These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 12821614)
1. More than just hype. Yusuf S; Dagenais G CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614 [No Abstract] [Full Text] [Related]
2. More than just hype. Fitchett D CMAJ; 2003 Jun; 168(13):1646-7; author reply 1647-8. PubMed ID: 12821613 [No Abstract] [Full Text] [Related]
3. [Added organ protection at little cost. Double savings with ACE inhibitors]. MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008 [No Abstract] [Full Text] [Related]
4. More than just hype. Sigal RJ CMAJ; 2003 Jun; 168(13):1647; author reply 1647-8. PubMed ID: 12821615 [No Abstract] [Full Text] [Related]
5. The renin angiotensin system and cardiovascular disease: hope or hype? Williams B J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):142-6. PubMed ID: 11967805 [No Abstract] [Full Text] [Related]
6. Ramipril use in Canada: HOPE or HYPE? Pilote L CMAJ; 2003 Mar; 168(5):568-9. PubMed ID: 12615751 [No Abstract] [Full Text] [Related]
7. Pharmacoeconomic impact of HOPE. Ostergren JB; Björholt I; Andersson F; Kahan T Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354 [TBL] [Abstract][Full Text] [Related]
8. [The reduction of cardiovascular risk with ramipril]. Vanuzzo D Ital Heart J Suppl; 2000 May; 1(5):713-4. PubMed ID: 10834142 [No Abstract] [Full Text] [Related]
9. Clinical decision making and the expected value of information. Willan AR Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257 [TBL] [Abstract][Full Text] [Related]
10. The HOPE study: comparison with other trials of secondary prevention. Otterstad JE; Sleight P Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962 [No Abstract] [Full Text] [Related]
14. [Therapy of hypertension. Cost conscious prevention of complications]. Kolloch RE MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042 [No Abstract] [Full Text] [Related]
15. Published pharmacoeconomic analyses: science or marketing? Henry D; Lang D Intern Med J; 2003; 33(9-10):403-4. PubMed ID: 14511190 [No Abstract] [Full Text] [Related]
16. More than just hype. Shishkov W CMAJ; 2003 Jun; 168(13):1647; author reply 1647-8. PubMed ID: 12821617 [No Abstract] [Full Text] [Related]
17. Effect of ramipril on cardiovascular events in high-risk patients. O'Rourke MF; Nichols WW N Engl J Med; 2000 Jul; 343(1):64-5; author reply 66. PubMed ID: 10896544 [No Abstract] [Full Text] [Related]
18. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model. Grover SA; Coupal L; Lowensteyn I Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211 [TBL] [Abstract][Full Text] [Related]
19. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? Grover SA; Coupal L; Lowensteyn I Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465 [TBL] [Abstract][Full Text] [Related]